A new obesity-drug startup, Syntis Bio, has emerged from stealth with $290 million in funding. Co-founded by entrepreneur Bob Langer, the biotech company is testing a novel approach to developing obesity treatments, aiming to compete with established drugs like Wegovy and Zepbound. Syntis Bio is focusing on the future of GLP-1 medicines, including a multiagonist approach, which is expected to play a significant role in the obesity treatment landscape.
GLP-1 agonists and their next-gen successors may still be center stage in the red-hot obesity space, but newly launched Syntis Bio is taking a different approach. https://t.co/m0FLJmH4ql
Biotech co-founded by Bob Langer is taking on a new approach to obesity https://t.co/2OISTt6dU1
Biotech co-founded by entrepreneur Bob Langer is testing a new approach to developing obesity treatments https://t.co/adyhvEhCSW via @ADeAngelis_bio
📍The future of GLP-1 medicines encompasses a multiagonist approach #obesity https://t.co/4hIcOQwP7T
This obesity-drug startup emerged from stealth with $290 million and plans to take on Wegovy and Zepbound https://t.co/HbyVVBP5Fy
The efficacy and safety of the new GLP-1 medicines continues to garner interest and will be discussed #ADA2024 Here is an updated safety-focused summary of the field and where it might be headed @DiabetesCareADA https://t.co/idKlbbzJFB #T2D #obesity https://t.co/rtEQYtHQG0